Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1179/crn.2006.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross-platform validation study.
Alzheimers Dement (Amst)
July 2023
Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience VU University Medical Center, Amsterdam UMC Amsterdam The Netherlands.
Introduction: Our previous antibody-based cerebrospinal fluid (CSF) proteomics study showed that Thimet oligopeptidase (THOP1), an amyloid beta (Aβ) neuropeptidase, was increased in mild cognitive impairment with amyloid pathology (MCI-Aβ+) and Alzheimer's disease (AD) dementia compared with controls and dementia with Lewy bodies (DLB), highlighting the potential of CSF THOP1 as an early specific biomarker for AD. We aimed to develop THOP1 immunoassays for large-scale analysis and validate our proteomics findings in two independent cohorts.
Methods: We developed in-house CSF THOP1 immunoassays on automated Ella and Simoa platforms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!